Literature DB >> 15231484

Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells.

Rhonda F Souza1, Kenneth Shewmake, Stephanie Pearson, George A Sarosi, Linda A Feagins, Ruben D Ramirez, Lance S Terada, Stuart J Spechler.   

Abstract

Cyclooxygenase-2 (COX-2) has been linked to neoplastic progression in Barrett's esophagus. Acid exposure has been shown both to activate the MAPK pathways and to increase COX-2 protein expression in Barrett's metaplasia, but it is not known whether these effects are interrelated. We hypothesized that acid-induced activation of the MAPK pathways mediates an increase in COX-2 expression in Barrett's esophagus, and we tested this hypothesis in a Barrett's-associated adenocarcinoma cell line (SEG-1). We exposed SEG-1 cells to acidic or neutral media in the presence and absence of two MAPK inhibitors: U-0126 (an ERK inhibitor) or SB-203580 (a p38 inhibitor). We quantitated COX-2 protein levels using an enzyme immunometric assay and COX-2 mRNA levels using real-time PCR. We also determined how acid affects the activity of the COX-2 promoter and mRNA stability. Compared with SEG-1 cells exposed to neutral media, acid-exposed cells exhibited a 2.8-fold increase in COX-2 mRNA levels within 30 min. Both U-0126 and SB-203580 attenuated the acid-induced increase in COX-2 mRNA. Acid significantly increased COX-2 protein expression and promoter activity, and both of these effects were abolished by treatment with U-0126 and SB-203580. Acid exposure also stabilized COX-2 mRNA levels, an effect that was abolished by U-0126 but not by SB-203580. We conclude that acid increases COX-2 expression through activation of the MAPK pathways. Acid-induced activation of both ERK and p38 causes a significant increase in COX-2 promoter activity, and acid-activated ERK stabilizes COX-2 mRNA. These findings suggest potential mechanisms whereby acid reflux might promote carcinogenesis in Barrett's esophagus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231484     DOI: 10.1152/ajpgi.00144.2004

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  22 in total

1.  Chemoprevention of esophageal adenocarcinoma.

Authors:  Julian A Abrams
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

2.  Signaling in H2O2-induced increase in cell proliferation in Barrett's esophageal adenocarcinoma cells.

Authors:  Xiaoxu Zhou; Dan Li; Murray B Resnick; Jose Behar; Jack Wands; Weibiao Cao
Journal:  J Pharmacol Exp Ther       Date:  2011-07-12       Impact factor: 4.030

3.  Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics.

Authors:  Jerzy Ostrowski; Michal Mikula; Jakub Karczmarski; Tymon Rubel; Lucjan S Wyrwicz; Piotr Bragoszewski; Pawel Gaj; Michal Dadlez; Eugeniusz Butruk; Jaroslaw Regula
Journal:  J Mol Med (Berl)       Date:  2007-03-30       Impact factor: 4.599

4.  Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.

Authors:  Reem Z Sharaiha; Daniel E Freedberg; Julian A Abrams; Y Claire Wang
Journal:  Dig Dis Sci       Date:  2014-05-03       Impact factor: 3.199

5.  Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma.

Authors:  Rihong Zhai; Feng Chen; Geoffrey Liu; Li Su; Matthew H Kulke; Kofi Asomaning; Xihong Lin; Rebecca S Heist; Norman S Nishioka; Chau-Chyun Sheu; John C Wain; David C Christiani
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

6.  Cytoprotective effects of acidosis via heat shock protein HSP27 against the anticancer drug doxorubicin.

Authors:  Anurag Kumar Singh; Michael P Manns; Ursula Seidler
Journal:  Cell Mol Life Sci       Date:  2010-08-22       Impact factor: 9.261

7.  The hyaluronic acid receptor CD44 coordinates normal and metaplastic gastric epithelial progenitor cell proliferation.

Authors:  Shradha S Khurana; Terrence E Riehl; Benjamin D Moore; Matteo Fassan; Massimo Rugge; Judith Romero-Gallo; Jennifer Noto; Richard M Peek; William F Stenson; Jason C Mills
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

8.  Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus.

Authors:  Judy S Wang; Andrea Varro; Charles J Lightdale; Nantaporn Lertkowit; Kristen N Slack; Michael L Fingerhood; Wei Yann Tsai; Timothy C Wang; Julian A Abrams
Journal:  Am J Gastroenterol       Date:  2009-11-10       Impact factor: 10.864

Review 9.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

10.  Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.

Authors:  Jorge-Shmuel Delgado; Reba Mustafi; Jason Yee; Sonia Cerda; Anusara Chumsangsri; Urszula Dougherty; Lev Lichtenstein; Alessandro Fichera; Marc Bissonnette
Journal:  Dig Dis Sci       Date:  2008-05-30       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.